About 27% of people lost 5% or more of their weight after one month, and 57% achieved this by 6 months
BPC-157 is not approved for human use by the FDA or any regulatory agency
Emerging evidence also suggests potential cardiovascular benefits, with some injectable GLP-1 receptor agonists demonstrating reduced risk of major adverse cardiovascular events in people with established cardiovascular disease
The duration of results varies from person to person, depending on what causes their RLS and how they respond to treatment
CD26 antigen is a surface dipeptidyl peptidase IV (DPPIV) as characterized by monoclonal antibodies clone TII-1947 and 4EL1C7
Nomiyama T, Kawanami T, Irie S, Hamaguchi Y, Terawaki Y, Murase K, Tsutsumi Y, Nagaishi R, Tanabe M, Morinaga H